Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OKYO by emailGet an email when OKYO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OKYO, unsubscribe in one click. Privacy
📣 What OKYO Says Is Next
second half of this year · “OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.”
Company press release, Sep 9, 2026 · SEC filing
in 2026 · “We anticipate topline results from this trial in 2026, with ongoing negotiations for clinical sites.”
Company press release, Jan 30, 2026 · SEC filing
this year · “OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP this year.”
Company press release, Jan 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OKYO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OKYO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.